Evelyne SÃ©gal-Bendirdjian

List of Publications by Year
in descending order

56 papers	2,063 citations	257450 24 h-index	243625 44 g-index
59 all docs	59 docs citations	59 times ranked	5432 citing authors

#	Article	IF	Citations
1	Exploring hTERT promoter methylation in cutaneous Tâ€cell lymphomas. Molecular Oncology, 2022, 16, 1931-1946.	4.6	12
2	hTERT DNA Methylation Analysis Identifies a Biomarker for Retinoic Acid-Induced hTERT Repression in Breast Cancer Cell Lines. Biomedicines, 2022, 10, 695.	3.2	2
3	Complex context relationships between DNA methylation and accessibility, histone marks, and hTERT gene expression in acute promyelocytic leukemia cells: perspectives for allâ€trans retinoic acid in cancer therapy. Molecular Oncology, 2020, 14, 1310-1326.	4.6	7
4	The long non coding RNA H19 as a biomarker for breast cancer diagnosis in Lebanese women. Scientific Reports, 2020, 10, 22228.	3.3	16
5	hMZF-2, the Elusive Transcription Factor. Frontiers in Genetics, 2020, 11, 581115.	2.3	1
6	The epigenetic regulator RINF (CXXC5) maintains SMAD7 expression in human immature erythroid cells and sustains red blood cells expansion.. Haematologica, 2020, Online ahead of print, 0-0.	3.5	2
7	Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer. Cancer Letters, 2019, 464, 5-14.	7.2	148
8	Non-canonical Roles of Telomerase: Unraveling the Imbroglio. Frontiers in Cell and Developmental Biology, 2019, 7, 332.	3.7	64
9	Modulation of lung cancer cell plasticity and heterogeneity with the restoration of cisplatin sensitivity by neurotensin antibody. Cancer Letters, 2019, 444, 147-161.	7.2	13
10	Telomerase regulation by the long non-coding RNA H19 in human acute promyelocytic leukemia cells. Molecular Cancer, 2018, 17, 85.	19.2	27
11	Platinum Complexes Can Bind to Telomeres by Coordination. International Journal of Molecular Sciences, 2018, 19, 1951.	4.1	5
12	Exploring the mechanism of inhibition of human telomerase by cysteineâ€reactive compounds. FEBS Letters, 2017, 591, 863-874.	2.8	5
13	Neurotensin regulation induces overexpression and activation of EGFR in HCC and restores response to erlotinib and sorafenib. Cancer Letters, 2017, 388, 73-84.	7.2	27
14	Neurotensin Receptor 1 Antagonist SR48692 Improves Response to Carboplatin by Enhancing Apoptosis and Inhibiting Drug Efflux in Ovarian Cancer. Clinical Cancer Research, 2017, 23, 6516-6528.	7.0	18
15	Association of a Platinum Complex to a G-Quadruplex Ligand Enhances Telomere Disruption. Chemical Research in Toxicology, 2017, 30, 1629-1640.	3.3	13
16	Heparan Sulfate Proteoglycans Promote Telomerase Internalization and MHC Class II Presentation on Dendritic Cells. Journal of Immunology, 2016, 197, 1597-1608.	0.8	16
17	WT1 expression is inversely correlated with MYCN amplification or expression and associated with poor survival in nonâ€MYCNâ€amplified neuroblastoma. Molecular Oncology, 2016, 10, 240-252.	4.6	9
18	A preclinical mouse model of glioma with an alternative mechanism of telomere maintenance (ALT). International Journal of Cancer, 2015, 136, 1546-1558.	5.1	23

#	Article	IF	Citations
19	Identification of human telomerase assembly inhibitors enabled by a novel method to produce hTERT. Nucleic Acids Research, 2015, 43, e99-e99.	14.5	12
20	cAMP-Dependent Protein Kinase A (PKA)â€“Mediated c-Myc Degradation Is Dependent on the Relative Proportion of PKA-I and PKA-II Isozymes. Molecular Pharmacology, 2015, 88, 469-476.	2.3	3
21	Pro-survival role of p62 during granulocytic differentiation of acute myeloid leukemia cells. Molecular and Cellular Oncology, 2014, 1, e970066.	0.7	8
22	p62/SQSTM1 upregulation constitutes a survival mechanism that occurs during granulocytic differentiation of acute myeloid leukemia cells. Cell Death and Differentiation, 2014, 21, 1852-1861.	11.2	53
23	Antitumor trans-N-Heterocyclic Carbeneâ€“Amineâ€“Pt(II) Complexes: Synthesis of Dinuclear Species and Exploratory Investigations of DNA Binding and Cytotoxicity Mechanisms. Journal of Medicinal Chemistry, 2013, 56, 2074-2086.	6.4	72
24	Activation of Both Protein Kinase A (PKA) Type I and PKA Type II Isozymes Is Required for Retinoid-Induced Maturation of Acute Promyelocytic Leukemia Cells. Molecular Pharmacology, 2013, 83, 1057-1065.	2.3	14
25	Cyclic AMP can promote APL progression and protect myeloid leukemia cells against anthracycline-induced apoptosis. Cell Death and Disease, 2013, 4, e516-e516.	6.3	29
26	Loss of the Malignant Phenotype of Human Neuroblastoma Cells by a Catalytically Inactive Dominant-Negative hTERT Mutant. Molecular Cancer Therapeutics, 2012, 11, 2384-2393.	4.1	15
27	cFos Mediates cAMP-Dependent Generation of ROS and Rescue of Maturation Program in Retinoid-Resistant Acute Promyelocytic Leukemia Cell Line NB4-LR1. PLoS ONE, 2012, 7, e50408.	2.5	3
28	hTERT Promotes Imatinib Resistance in Chronic Myeloid Leukemia Cells: Therapeutic Implications. Molecular Cancer Therapeutics, 2011, 10, 711-719.	4.1	24
29	Epigenetic plasticity of hTERT gene promoter determines retinoid capacity to repress telomerase in maturation-resistant acute promyelocytic leukemia cells. Leukemia, 2010, 24, 613-622.	7.2	27
30	The telomere story or the triumph of an open-minded research. Biochimie, 2010, 92, 321-326.	2.6	19
31	Telomerase regulation in hematological cancers: A matter of stemness?. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2009, 1792, 229-239.	3.8	25
32	Functional involvement of RINF, retinoid-inducible nuclear factor (CXXC5), in normal and tumoral human myelopoiesis. Blood, 2009, 113, 3172-3181.	1.4	47
33	Telomeres and telomerase: From basic research to clinical applications. Biochimie, 2008, 90, 1-4.	2.6	16
34	Telomerase targeting by retinoids in cells from patients with myeloid leukemias of various subtypes, not only APL. Leukemia, 2006, 20, 599-603.	7.2	18
35	Diagnostics, Prognostic and Therapeutic Exploitation of Telomeres and Telomerase in Leukemias. Current Pharmaceutical Biotechnology, 2006, 7, 171-183.	1.6	10
36	Telomeres and Telomerase: Pharmacological Targets for New Anticancer Strategies?. Current Cancer Drug Targets, 2006, 6, 147-180.	1.6	66

#	Article	IF	Citations
37	Immunodetection of human telomerase reverse-transcriptase (hTERT) re-appraised: nucleolin and telomerase cross paths. Journal of Cell Science, 2006, 119, 2797-2806.	2.0	112
38	Retinoid/arsenic combination therapy of promyelocytic leukemia: induction of telomerase-dependent cell death. Leukemia, 2005, 19, 1806-1811.	7.2	38
39	Inhibition of human telomerase by oligonucleotide chimeras, composed of an antisense moiety and a chemically modified homo-oligonucleotide. FEBS Letters, 2005, 579, 1411-1416.	2.8	18
40	Death receptor signaling regulatory function for telomerase: hTERT abolishes TRAIL-induced apoptosis, independently of telomere maintenance. Oncogene, 2004, 23, 7469-7474.	5.9	76
41	Retinoic acid receptor Î± and retinoid-X receptor-specific agonists synergistically target telomerase expression and induce tumor cell death. Oncogene, 2003, 22, 9142-9150.	5.9	40
42	Apoptosome-independent Pathway for Apoptosis. Journal of Biological Chemistry, 2003, 278, 29571-29580.	3.4	34
43	Staurosporine induces apoptosis through both caspase-dependent and caspase-independent mechanisms. Oncogene, 2001, 20, 3354-3362.	5.9	366
44	Orchestration of multiple arrays of signal cross-talk and combinatorial interactions for maturation and cell death: another vision of t(15;17) preleukemic blast and APL-cell maturation. Oncogene, 2001, 20, 7161-7177.	5.9	32
45	Retinoids down-regulate telomerase and telomere length in a pathway distinct from leukemia cell differentiation. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 6662-6667.	7.1	90
46	Autonomous Rexinoid Death Signaling Is Suppressed by Converging Signaling Pathways in Immature Leukemia Cells. Molecular Endocrinology, 2001, 15, 1154-1169.	3.7	49
47	Ectopic expression of Bcl-2 switches over nuclear signalling for cAMP-induced apoptosis to granulocytic differentiation. Cell Death and Differentiation, 2000, 7, 1081-1089.	11.2	21
48	Nuclear Translocation of a Leukocyte Elastase Inhibitor/Elastase Complex during Staurosporine-Induced Apoptosis: Role in the Generation of Nuclear L-DNase II Activity. Experimental Cell Research, 2000, 254, 99-109.	2.6	63
49	Alteration in p53 pathway and defect in apoptosis contribute independently to cisplatin-resistance. Cell Death and Differentiation, 1998, 5, 390-400.	11.2	18
50	Isolation of Mitochondrial DNA-less Mouse Cell Lines and Their Application for Trapping Mouse Synaptosomal Mitochondrial DNA with Deletion Mutations. Journal of Biological Chemistry, 1997, 272, 15510-15515.	3.4	64
51	Isolation and Characterization of Mitochondrial DNA-less Lines from Various Mammalian Cell Lines by Application of an Anticancer Drug, Ditercalinium. Biochemical and Biophysical Research Communications, 1997, 239, 257-260.	2.1	48
52	Cisplatin Resistance in a Murine Leukemia Cell Line Is Associated with a Defective Apoptotic Process. Experimental Cell Research, 1995, 218, 201-212.	2.6	60
53	Inhibition of DNA topoisomerases I and II and induction of apoptosis by erbstatin and tyrphostin derivatives. Biochemical Pharmacology, 1994, 48, 549-560.	4.4	29
54	Evidence for a reverse transcription intermediate for a marked line transposon in tumoral rat cells. Biochemical and Biophysical Research Communications, 1991, 181, 863-870.	2.1	21

#	Article	IF	Citations
55	Selective alteration of mitochondrial function by ditercalinium (NSC 335153), a DNA bisintercalating agent. Biochemical Pharmacology, 1990, 39, 109-122.	4.4	11
56	Telomeres and Telomerase in Neuroblastoma. , 0, , .		1